Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Efficacy and safety of Yi'anning pills for stable angina pectoris in coronary heart disease with -blood and liver-kidney deficiency syndrome: a multicenter, randomized, double-blind, superiority clinical trial.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of Yi'anning pills for the treatment of stable angina pectoris in coronary heart disease with
methodsThis study was a multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial. Participants were randomly divided into the experimental group and the control group (3∶1) using the randomized block method. All participants received guideline-standardized treatment for stable angina pectoris associated with coronary heart disease, among whom the first 64 participants underwent the treadmill exercise test. The experimental group was also treated with Yi'anning pills and Xinyuan capsules simulant, while the control group received Yi'anning pills simulant and Xinyuan capsules, both for 8 weeks. The primary clinical outcome was the total Seattle Angina Questionnaire (SAQ) score, and the secondary clinical outcomes were the individual SAQ scores, treadmill exercise test results, rate of nitroglycerin cessation or reduction, classification of angina pectoris severity, and therapeutic effect against Traditional Chinese Medicine syndrome.
resultsOverall, 158 participants were included from nine sub-centers, including 119 in the experimental group and 39 in the control group. After 8 weeks of treatment, the experimental intervention was superior to the control intervention in terms of the increase in total SAQ score (
conclusionBased on the standardized treatment of stable angina pectoris in coronary heart disease, Yi'anning pills outperformed Xinyuan capsules in terms of the total SAQ score, demonstrating a good clinical effect and safe application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.